Wolfe Research Reiterates Peerperform Rating on Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY) PT Raised to $307 at BofA Securities

BofA Securities analyst Tazeen Ahmad raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $307.00 (from $295.00) while maintaining a Buy rating.

The analyst comments "ALNY hosted an analyst reception after the detailed HELIOS-B data at ESC (see Aug 30 note). The main... More

Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Stifel analyst Paul Matteis reiterated a Buy rating and $295.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst comments "With a few days to reflect, full HELIOS-B data were slightly less compelling than we expected, simply because we thought the results might offer... More

TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

TD Cowen analyst Ritu Baral reiterated a Buy rating and $282.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented, "ALNY hosted an ESC investor event to highlight the HELIOS-B data detail, and its support of vutri 1L tx. Additive... More

H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $400.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented: "On August 30, Alnylam presented additional data from the Phase 3 program (HELIOS-B) evaluating AMVUTTRA (vutrisiran) in patients with ATTR amyloidosis with... More

Barclays Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY)

Barclays analyst Gena Wang reiterated an Overweight rating and $295.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst comments "Key takeaways. At ESC 2024, ALNY presented detailed data from Ph3 HELIOS-B, showing all- cause-mortality (ACM) reduction was stat sig at 33-36 mon (HR 0.694, p=0.0389), with... More

Citi Reiterates Neutral Rating on Alnylam Pharmaceuticals (ALNY)

Citi analyst David Lebowitz reiterated a Neutral rating and $275.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst comments "Next steps: Additional data in Sep with regulatory filing on track for late 2024. Looking ahead, Alnylam plans to share additional data at the Heart... More

Alnylam Pharma (ALNY) Management Said There Was a Typo Error on Discussant Slide - Stat

Alnylam Pharma (NASDAQ: ALNY) Management Said There Was a Typo Error on Discussant Slide - Stat

On $ALNY call, management said there was a typo error on this discussant slide. At 30 months, ACM RRR was 31%, not 13% pic.twitter.com/pLRJaNmkB5

BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) following HELIOS-B readout

BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $300.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented: "HELIOS-B data demonstrate: (1) Separation between Amvuttra/placebo ACM curves by ~19mo, similar to stabilizers; (2) Strong Amvuttra effect on top of Tafamidis,... More

Stifel Reiterates Alnylam Pharmaceuticals (ALNY) at Buy following HELIOS-B readout, 'full HELIOS-B data look strong'

(Updated - August 30, 2024 7:58 AM EDT)

Stifel analyst Paul Matteis reiterated a Buy rating and $295.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented: "Overall we think full HELIOS-B data look strong, de-risking approval and a blockbuster opportunity, while also... More

Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises

Alnylam Pharma (NASDAQ: ALNY) shares tumbled 11.5% Friday following the release of results from its HELIOS-B Phase 3 study of vutrisiran, despite the study meeting all primary and secondary endpoints.

The investigational RNAi therapeutic, aimed at treating ATTR amyloidosis with cardiomyopathy (ATTR-CM), was shown to reduce the risk of death and cardiovascular events by 28% compared to placebo in the overall... More

Alnylam Pharma (ALNY) Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).

The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously... More